TNF-Bound Colloidal Gold in Treating Patients With Advanced Solid Tumors

DISEASE CHARACTERISTICS:

* Histologically confirmed solid tumor
* Advanced and/or metastatic disease
* Unresponsive to conventional therapy (i.e., disease progressed while receiving any known standard curative or palliative therapy) OR previously untreated tumor for which no standard treatment exists
* Measurable or evaluable metastatic disease
* No lymphoma or other hematologic malignancy
* No known brain metastases

  * Previously treated brain metastases with no evidence of recurrence allowed

PATIENT CHARACTERISTICS:

* ECOG performance status 0-2
* Life expectancy ≥ 3 months
* Absolute neutrophil count ≥ 1,500/mm³
* Platelet count ≥ 100,000/mm³
* Creatinine ≤ 2.0 mg/dL
* Bilirubin ≤ 2.5 mg/dL
* ALT and AST ≤ 1.5 times upper limit of normal (ULN) (3 times ULN if liver metastases are present)
* Alkaline phosphatase ≤ 1.5 times ULN (3 times ULN if liver metastases are present)
* Prothrombin time ≤ 1.5 times ULN
* Hemoglobin ≥ 10.0 g/dL (transfusion allowed)
* LVEF ≥ 45% by echocardiogram or thallium stress test for patients \> 50 years of age or history of cardiovascular disease
* FEV\_1 and DLCO \> 30% of predicted for patients with a history of pulmonary disease
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No active bacterial or viral infection with systemic manifestations (e.g., fever, symptoms, leukocytosis)

  * Localized chronic infections, such as mild acne or tinea pedis allowed
* No acute or chronic viral hepatitis
* No known bleeding disorder
* No other concurrent life-threatening illness, including any of the following:

  * Unstable angina
  * Severe oxygen-dependent chronic obstructive pulmonary disease
  * End-stage liver disease
* No known active renal disease or renal insufficiency as evidenced by serum creatinine \> 2.0 mg/dL
* No HIV positivity

PRIOR CONCURRENT THERAPY:

* Recovered from prior therapy
* More than 3 weeks since prior biological or cytotoxic agents (6 weeks for nitrosoureas)
* No known requirment for palliative treatment
* No concurrent surgery
* No other concurrent anticancer therapy